Barbara Gripshover, MD
Associate Professor, Case Western Reserve University
Medical Director, John T. Carey Special Immunology Unit
Phone: (216) 844-5876
Fax: (216) 844-1632
E-mail:gripshover.barb@clevelandactu.org
Education
MD - Vanderbilt University, 1987
Internal Medicine Residency- University Hospitals of Cleveland, 1990
Infectious Diseases- Case Western Reserve University/University Hospitals of Cleveland, 1993
Research
• Antiretroviral therapy including salvage therapy
• Complications of antiretroviral therapy
Special Clinical Interests
HIV/AIDS
Selected References:
• Shafer RW, Smeaton LM, Robbins GK, DeGruttola V, Snyder SW, D/Aquila RT, Johnson VA, Morse GD, Nokta MA, Martinez AI, Gripshover BM, Kaul P, Haubrich R, Swingle M, McCarty SD, Vella S, Hirsch MS, Merigan TC. AIDS Clinical Trials Group 384 Team. Comparison of four-drug regimens and pairs of three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med. 2003 Dec 11;349(24):2304-15.
• Valdez H, Chowdhury T, Assad R, Woolley I, Davis T, Davidson R, Beinker N, Gripshover BM, Salata RA, McComsey G, Weissman SB, Lederman MM. The Changing Spectrum of Mortality Due to Human Immunodeficiency Virus: Analysis of 260 Deaths from 1995-1999. Clin Infect Dis 2001 May 15;32(10):1487-93.
•Valdez H, Lederman MM, Woolley I, Walker CJ, Vernon LT, Hise A, and Gripshover BM. HIV-1 protease inhibitors in a clinical practice: predictors of virologic outcome. Archives of Internal Medicine 159:1771-1776, 1999.
• Gripshover BM, Valdez H, Salata RA and Lederman MM. Withdrawal of fluconazole suppressive therapy for thrush in patients responding to combination antiviral therapy including protease inhibitors. AIDS 12(18):2513-2514, 1998.
| 
